Pharmacokinetic evaluation of darbepoetin alfa for the treatment of pediatric patients with chemotherapy‐induced anemia
Pediatric Blood & Cancer2006Vol. 49(5), pp. 687–693
Citations Over Time
Abstract
The pharmacokinetic profile of darbepoetin alfa indicated that it was slowly absorbed and exhibited a long terminal half-life in these pediatric study patients with CIA.
Related Papers
- → Darbepoetin Alfa(2001)66 cited
- → Darbepoetin alfa administered monthly maintains haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis: A multicentre, open‐label, Australian study(2007)19 cited
- [Treatment of renal anemia with darbepoetin alfa: results of an Austrian multicenter study].(2002)
- → Darbepoetin alfa: A new erythropoietic drug for the treatment of renal anaemia*(2002)7 cited
- → Pharmacokinetic evaluation of darbepoetin alfa for the treatment of pediatric patients with chemotherapy‐induced anemia(2006)6 cited